Latest ebit for HAVN.CN: $-17M, below the Healthcare sector average of $1.9T.
Get informed when a big investor buys or sells
+ FollowAs of Jan 31, 2023
Trailing 12 months ending Jan 31, 2023
HAVN Life Sciences (HAVN.CN) currently reports a EBIT of $-17M as of January 2023. That compares with $-22M in the prior-year period — up 24.4% year over year. That is below the Healthcare sector average of $1.9T. Use the charts on this page to explore HAVN Life Sciences's EBIT history and peer comparisons.
HAVN Life Sciences's EBIT increased from $-22M to $-17M — a 24.4% year-over-year increase (period ending January 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.
HAVN Life Sciences's EBIT of $-17M is lower than the Healthcare sector average of $1.9T. That is roughly 100.0% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
HAVN Life Sciences reported $-17M in EBIT as of January 2023. That compares with $-22M in the prior-year period — up 24.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.
Start with the current EBIT of $-17M, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is $1.9T. From there, open related valuation or income-statement pages for HAVN Life Sciences, and consider following HAVN.CN for alerts when major investors trade the stock.